# Engineered CAR T cells clear senescent cells and reduce fibrosis in animal models

- Published: 2026-11-07 03:32 UTC
- Section: Life & Health › Biotechnology
- Tags: CAR T cell therapy, senescent cells, senolytics, fibrosis reversal, aging biology, uPAR CAR T, synNotch logic gates, preclinical models
- URL: https://realtech.media/news/rt-0bd4e89bac6c5951b497b02b_engineered_car_t/

**Researchers reviewed the adaptation of CAR T cell platforms to eliminate senescent cells, achieving an 87% clearance rate in mouse models.**

![Engineered CAR T cells clear senescent cells and reduce fibrosis in animal models](https://realtech.media/media/2026/11/f145945170088d6f.jpg)
*Syed Sajidul Islam, Wikimedia Commons, CC BY-SA 4.0*

Scientists reviewed the application of chimeric antigen receptor (CAR) T cell therapy against senescent cells in a paper published in Research [1]. The work examines the transition of cancer immunotherapy concepts to aging-associated pathologies. The authors analyzed preclinical data on specific cell-surface targets, genetic engineering strategies, and physiological outcomes across animal models of fibrosis and organ dysfunction.

Senescent cells cease division while secreting pro-inflammatory and profibrotic factors known as the senescence-associated secretory phenotype (SASP). First-generation small-molecule senolytics face limitations such as transient efficacy, poor tissue distribution, and modest target specificity. By contrast, engineered CAR T cells provide antigen-directed cytotoxic activity and in vivo expansion capabilities [1].

## Preclinical target validation

Preclinical studies evaluated multiple cell-surface antigens, including uPAR, NKG2D ligands, FAP, PDGFR, and CCR2. In liver fibrosis models, single-cell analysis showed over 60% co-expression of uPAR with p16. A single dose of uPAR-targeting CAR T cells reduced senescent cells by 87% and liver collagen deposition by 52% in mice, while also improving metabolic markers and exercise tolerance [1]. For NKG2D, ligands such as MICA showed approximately twofold higher expression on senescent cells, and NKG2D-directed CAR T cells selectively cleared damaged cells induced by various stressors [1]. Additionally, CAR T constructs targeting FAP and PDGFRβ reduced collagen volume and improved cardiac ejection fraction and renal performance in animal models.

## Engineering logic circuits and safety controls

Because senescent cells play active physiological roles in wound healing and tissue repair, indiscriminate elimination presents risks of off-target toxicity and cytokine release syndrome. To restrict targeting to pathological cells, investigators propose multi-antigen synNotch AND logic gates along with switchable suicide systems, including iCasp9 and HSVTK cassettes [1]. Manufacturing adaptations for cells derived from aged donors include selecting naive CD45RA+CCR7+CD62L+ phenotypes, employing IL-15 and IL-7 cytokine supplementation, and applying TERT mRNA electroporation, which extended telomeres by approximately 0.9 kb across 43 population doublings [1]. The authors emphasize that all evaluated anti-senescence CAR T therapies remain strictly at the preclinical stage.

## Sources

1. [Research](https://doi.org/10.34133/research.1326)
2. [EurekAlert](https://www.eurekalert.org/news-releases/1150732)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-0bd4e89bac6c5951b497b02b_engineered_car_t/